James Mason, DO
Hematology & Oncology · Ogden, UTNPI 1114362001
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,092 of the $1,309 with a category attached, or 83.5%. 11 manufacturers reported payments, led by Johnson & Johnson at 32.2% of the total. Reporting peaked in 2023 at $524 and has fallen 61.8% since, to $200 in 2025. That places this record below the midpoint for hematology & oncology clinicians in UT, where the typical reported total is $2,350.
Across 16 payments — averaging $81.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$422
- Incyte Corporation$301
- Takeda Pharmaceuticals U.S.A., Inc.$106
- GSK$105
- Genmab U.S., Inc.$102
- Astellas Pharma US Inc$101
- plus $172 from 5 others
Across 73 payments — averaging $5767.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$342K
- Taiho Oncology, Inc.$42K
- Otsuka Pharmaceutical Co., Ltd.$37K
What the payments were for
- Food & beverage$1,09283%
- Education$21617%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 4 | $422 |
| Incyte Corporation | 3 | $301 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $106 |
| GSK | 1 | $105 |
| Genmab U.S., Inc. | 1 | $102 |
| Astellas Pharma US Inc | 1 | $101 |
| AstraZeneca | 1 | $78 |
| Lilly USA, LLC | 1 | $44 |
| Bristol Myers Squibb | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,309 in reported general payments places this provider in the 35th percentile of 77 hematology & oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 32 | $720,574 |
| IdhifaEnasidenib Mesylate | 13 | $601,976 |
| CalquenceAcalabrutinib Maleate | 38 | $530,136 |
| BrukinsaZanubrutinib | 24 | $356,152 |
| SprycelDasatinib | 17 | $296,426 |
| Lenalidomide | 20 | $290,951 |
| RevlimidLenalidomide | 15 | $257,425 |
| NinlaroIxazomib Citrate | 14 | $205,353 |
| VenclextaVenetoclax | 18 | $194,255 |
| InqoviDecitabine/Cedazuridine | 12 | $102,237 |
| EliquisApixaban | 79 | $72,671 |
| Imatinib Mesylate | 38 | $43,027 |
| XareltoRivaroxaban | 22 | $17,592 |
| Deferasirox | 37 | $6,664 |
| Anagrelide Hcl | 11 | $4,367 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbIdhifa, Revlimid | $18 | $859,40128 claims |
| AstraZenecaCalquence | $78 | $530,13638 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $106 | $205,35314 claims |
| Johnson & JohnsonXarelto | $422 | $17,59222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 77 hematology & oncology providers in Utah.
Other hematology & oncology in Ogden
- Belisario ArangoOgden$374K
- Carl GrayOgden$19K
- Joshua RamsayOgden$14K
- David CasselOgden$2K
- Vincent HansenOgden$509
- Douglas SborovSalt Lake City$473K
- Mark LewisMurray$319K
- Daniel CourielSalt Lake City$229K
- Shiven PatelSalt Lake City$223K
- Neeraj AgarwalSalt Lake City$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.